GHK-Cu returned to FDA’s interim compounding category. Injection was excluded.

Why this note exists

Compounding-list news is usually reported as a scoreboard: a substance is on, or it is off. GHK-Cu is a case where the interesting thing happened inside a qualifier. In the space of two weeks FDA took the substance off category 1, then put a narrower version of it back, and the difference between the two versions is exactly the difference between a cream and a vial.

A note on what kind of evidence this is: the regulatory facts below are quoted from FDA's own published documents rather than paraphrased, because the wording is doing the work. Every efficacy figure is human data and carries its design and participant count. One paragraph reports animal and in vitro findings and is labeled as such in its first sentence. Listing counts come from pepmg's price index. pepmg does not convert any of this into a protocol, and sells nothing.

What changed

Removed on April 22. Added back, narrower, on May 5.

The primary document is FDA's running list of bulk drug substances nominated for use in compounding under section 503A, updated May 14, 2026.[1] Its update section records the sequence in two sentences. GHK-Cu "was removed from category 1 on April 22, 2026, because the nominations for GHK-Cu were withdrawn by the nominators."[1] Then: "On May 5, 2026, one of those nominators clarified that it intended to withdraw only its nomination of the injectable route of administration with respect to GHK-Cu and would like to retain its nomination for GHK-Cu for non-injectable routes of administration."[1]

The consequence is stated in the next line — "GHK-Cu (except for injectable routes of administration) will be added back to category 1" — and the category 1 list in the same document carries that entry verbatim, between Ferric Subsulfate and Glutaraldehyde.[1]

The same document adds a forward-looking commitment: "FDA has announced it intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list."[1] That meeting had not been scheduled publicly as of this writing — FDA's 2027 PCAC meeting-materials page carried no posted agenda when checked on September 9, 2026.[20] GHK-Cu was not among the substances the committee took up at its July 23–24, 2026 meeting.[19]

The other half

Where the injectable route went

It did not vanish. It appears on a different FDA page, the one for substances that may present significant safety risks, under a heading for "[b]ulk drug substances nominated but withdrawn" — described there as substances "previously in category 2 of the interim policies [that] were withdrawn by the nominators."[2] The entry is headed "GHK-Cu (for injectable routes of administration)" and reads in full: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations."[2]

Two things are true about that paragraph at once, and both matter. It is FDA writing down a concern about injecting this peptide, in FDA's own words, on FDA's own safety page. And it is not a determination that injecting GHK-Cu is unsafe — the mechanism FDA names is immunogenicity risk from aggregation and impurities, which is a manufacturing-and-characterization concern about compounded products, and the entry is filed under nominations that were withdrawn rather than nominations FDA rejected.[2] The honest summary is that FDA has published a stated concern and has not published a finding.

The categories themselves are worth quoting because they are routinely oversold. Category 1 substances "may be eligible for inclusion on the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list," and FDA "does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met."[3][4] Category 2 is where FDA "has identified significant safety risks relating to the use of these substances in compounding pending further evaluation" and where the agency "would consider taking action against a compounder … under its general enforcement policies."[3]

Neither category is an approval, and neither is about a research vial. The whole apparatus governs what a licensed pharmacist or physician may compound for an identified patient. There is no FDA-approved drug product whose active ingredient is GHK-Cu; a Drugs@FDA query on September 9, 2026 returned none.[5] Copper tripeptide-1, the name the same molecule carries on cosmetic ingredient lists, sits under a different regime entirely: FDA states that cosmetic products and ingredients other than color additives do not require FDA approval before going on the market.[6]

The human record

One randomized human study of the peptide alone. Thirteen patients, and it missed.

A PubMed search on September 9, 2026 for GHK-Cu, copper tripeptide, copper peptide or glycyl-L-histidyl-L-lysine in title or abstract returned 189 records; filtered to human subjects and clinical-trial publication types, it returned one.[10]

That one is a 2006 study in Archives of Facial Plastic Surgery. Patients undergoing circumoral CO₂ laser resurfacing were randomized to post-treatment skin regimens with or without a GHK-Cu product; 13 completed. The authors report that "[c]omputer analysis and blinded evaluators found no statistically significant differences between groups for earlier resolution of erythema," that all patients improved but "no differences were found between groups," and that the one endpoint that did separate was a patient questionnaire on overall skin quality (P = .04).[10] Their own conclusion is that the products "offered no significant reduction or resolution of posttreatment erythema" and that "[o]bjective evaluation found no significant improvement in wrinkles or overall skin quality."[10]

Designs and participant counts as reported by the papers themselves. None of the three isolates GHK-Cu as a single agent by injection.[10][11][12]

The two larger-sounding human reports both dissolve on inspection, and they dissolve the same way. The 2018 hair study injected 1,000 patients intradermally — but with "a recombinant, bioengineered hair formulation" containing vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor, keratinocyte growth factor, thymosin β4 and copper tripeptide-1, in an "open-label, prospective, single-arm interventional pilot study" with no control group.[11] It is the largest human study in which anything called copper tripeptide was injected, and its design makes it incapable of telling you what the copper tripeptide did. The 2016 crow's-feet report is one 59-year-old man treated weekly for 12 weeks with a jet device and a solution of copper-GHK plus oligo-hyaluronic acid, rhodiola extract, tranexamic acid and β-glucan.[12] One patient, five actives, a device.

Two 2026 narrative reviews written for clinicians reach the same place from the outside. The American Journal of Sports Medicine primer on injectable peptide therapy, which evaluated BPC-157, TB-4/TB-500, CJC-1295 with ipamorelin, tesamorelin and GHK-Cu, states that "GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions."[13] A Sports Medicine review the same year places GHK-Cu among direct-to-patient peptides where "rigorous human safety data are scarce."[14] Both are narrative reviews, not systematic ones, and are cited here as expert summaries rather than as evidence in themselves.

What is running now, and what it will and will not answer

A repeat ClinicalTrials.gov intervention search on September 18, 2026 returned three records, including a multi-ingredient device study.[9] None of these records tests injection of GHK-Cu as a single ingredient.

The dedicated single-ingredient study is NCT07437586: "A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults."[7] Sixty healthy adults, quadruple-masked, sponsor Hudson Biotech, sites in China, a 0.1% w/w gel applied once daily for 14 days, primary outcome "[t]ime to complete re-epithelialization (days) of each wound."[7] It started February 2, 2026 and was still recruiting when checked.[7] That is a real, well-controlled design — a split-wound comparison inside the same person is about as clean as a topical wound study gets — and a result would add controlled single-ingredient evidence. It will be a result about a topical gel on standardized acute wounds in healthy volunteers.

The second, NCT07706361, is a randomized 100-participant study by LifeWave, Inc. of its X39 patch, with primary outcomes measuring change in circulating GHK and GHK-Cu levels from baseline to day 8.[8] It measures the body's own levels of the tripeptide; it does not give anyone GHK-Cu. Listed as not yet recruiting with a January 2027 start.[8]

A publication-day registry check also identifies NCT05932732, a completed 27-person study of Hydrafacial devices with a multi-ingredient serum that includes copper peptide. It cannot isolate the effect of GHK-Cu. The patch study measures circulating levels without administering GHK-Cu; the single-ingredient gel trial asks a different question.[22][7][8]

There is a complication in the topical direction too, and it belongs here rather than in a footnote. A 2025 review in Molecules describes GHK-Cu as "a fairly hydrophilic compound with limited permeation through the lipophilic stratum corneum," and concludes after surveying the literature that the transport of liposome-encapsulated GHK-Cu "received little attention," calling it a research gap.[17] The route FDA is still evaluating is also the route with an unresolved delivery question.

The preclinical literature, labeled as preclinical

Everything in this paragraph is animal or in vitro work and none of it is human evidence. Recent GHK-Cu research is overwhelmingly at the bench. A 2024 Redox Biology paper reports that GHK-Cu attenuated lung inflammation and fibrosis in an experimental silicosis mouse model, with mechanistic work in the RAW264.7 macrophage cell line, identifying peroxiredoxin 6 as a binding target.[15] A 2025 Nature Communications paper describes a dimeric copper peptide in a hydrogel as a proof of concept for diabetic wound healing.[16] The paper that supplies the widely repeated background claim — that GHK is "a tripeptide naturally occurring in human blood and urine" with antioxidant effects — is the same mouse study.[15]

Much of the mechanistic story circulating in peptide marketing traces back further, to review articles rather than trials. The most cited of them, a 2015 BioMed Research International review of GHK in skin regeneration, lists all three authors' affiliation as "Skin Biology, Research & Development Department" in Bellevue, Washington — a copper-peptide skincare company.[18] That does not make the review wrong. It does mean a reader tracing a mechanism claim back to its source should know where the source sits.

The market

The compound almost every vendor stocks, in the form the list excludes

GHK-Cu's position in this market is close to universal. In the index generated September 8, 2026 it ranks second of 87 compounds by vendor coverage, behind BPC-157 by one vendor: 103 of 108 vendors carry it, across 231 listings, 219 of them in stock.[21] The dominant format is a lyophilized vial — pepmg classifies 222 of the 231 that way — most commonly 100 mg (83 listings) or 50 mg (73).[21] The non-injectable formats FDA's category 1 entry now describes account for nine listings in total: four topical preparations and five capsule products.[21]

One more detail from the index, offered as an observation rather than an accusation: 24 of the 231 listings use the word "copper" anywhere in the product name.[21] pepmg makes no claim about the contents of any vendor's vial, and reports only what the listings themselves say.

Three things this note is not saying

First, it is not saying FDA found injectable GHK-Cu dangerous. FDA published a stated concern — immunogenicity risk from aggregation and peptide-related impurities, and limited human data — on a page about potential risks, in an entry whose nomination was withdrawn by the nominator rather than rejected by the agency.[2] A published concern and a finding are different documents.

Second, it is not saying GHK-Cu does not work. It is saying that after decades of interest the controlled human record for the peptide alone amounts to one 13-patient study that missed its objective endpoints, and that a further controlled single-ingredient efficacy trial is still recruiting.[10][7] Absence of evidence is being reported here as absence of evidence.

Third, it is not saying the category 1 listing is a green light for the topical form either. Category 1 is an interim enforcement posture during an evaluation FDA has not finished, on a substance FDA says it intends to bring to an advisory committee before the end of February 2027.[1][3]

What it is saying is narrow and, for once, entirely contained in a piece of punctuation. FDA's live entry for this compound is "GHK-Cu (except for injectable routes of administration)."[1] Nine of the 231 listings in pepmg's index are on the inside of that bracket.[21]

Questions people are asking